Promising Long-Term Data and Upcoming Catalysts Drive Buy Rating for Rocket Pharmaceuticals
Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) and keeping the price ...
Buy Rating for ARCT Driven by Strategic Insights and Promising Vaccine Prospects
Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on ARCT stock, giving a Buy rating on November 8. Discover the latest stocks recommended by top Wall Street analysts, ...
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...